STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of BioClinica, Inc. (“BioClinica” or the “Company”) (Nasdaq: “BIOC”) and other violations of state law by the board of directors of BioClinica relating to the proposed acquisition of the Company by private equity firm JLL Partners, Inc. The firm’s investigation seeks to determine, among other things, whether the board of directors of BioClinica breached their fiduciary duties by failing to maximize shareholder value.
Under the terms of the proposed transaction, BioClinica shareholders will receive $7.25 in cash for each share of common stock they own. The transaction is currently being valued at approximately $123 million. According to Yahoo! Finance, the median and high analyst price target was $9.00 per BioClinica share just prior to the announcement of the proposed transaction.
If you currently own common stock of BioClinica and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at email@example.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.